Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia

Ningbo No. 1 Hospital

Status: Invitation-only

Conditions: Metabolically Healthy Obesity; Hyperuricemia; Metabolic Dysfunction-Associated Steatotic Liver Disease

Study type: Observational

Funder types: Other

Identifiers

NCT07001865

2025-073RS-01

MR-33-25-026108 (Other Identifier)

Details and patient eligibility

About

Although metabolically healthy obesity (MHO) is often considered a relatively benign obesity, its association with the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and hyperuricemia remains unclear. This study examined the associations between MHO and other metabolic-obesity phenotypes with MASLD and hyperuricemia, and explored the mediating roles of metabolic indicators.This study included 11,712 and 13,846 participants from a health examination cohort at the First Affiliated Hospital of Ningbo University for MASLD and hyperuricemia analyses, respectively. Participants were classified into four metabolic-obesity phenotypes, with MHO defined as obesity without metabolic syndrome components. The outcomes were MASLD and hyperuricemia. Cox regression and mediation analyses were conducted to assess associations and mediating effects.

Enrollment: 17,040 estimated patients

Sex: All

Ages: 18 to 100 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Underwent comprehensive health examinations at the Physical Examination Center of the First Affiliated Hospital of Ningbo University between 2017 and 2024;
2. Aged 18 years or older at baseline;
3. Completed an abdominal ultrasound examination during the health check-up.

Exclusion criteria

1. Underweight status at baseline, defined as BMI < 18.5 kg/m² ；
2. Missing data on height, weight, or components of the metabolic syndrome ;
3. Baseline diagnosis of MASLD or any other liver diseases
4. Baseline diagnosis of hyperuricemia

Trial design

17,040 participants in 2 patient groups

MASLD cohort

Description:

participants with non-MASLD at baseline

Hyperuricemia

Description:

participants with non-Hyperuricemia at baseline